Patients with chronic kidney disease (CKD) frequently experience iron deficiency anemia (IDA); there is an association between IDA and adverse outcomes in this patient population.
Patients with IDA and CKD are commonly undertreated. Poor absorption of conventional iron agents as well as gastrointestinal side effects result in insufficient effectiveness of those agents, creating a need for novel oral iron preparations.
Pablo E. Pergola, MD, and colleagues reviewed current treatment guidelines for patients with anemia and CKD in an article published in Advances in Chronic Kidney Disease [2019;26(4):272-291]. The review included clinical trial data for iron-repletion agents being used currently, as well as novel oral iron therapies in development.
Ferric citrate is a novel iron-repletion agent approved for use in patients with non–dialysis-dependent CKD and IDA; results of trials found improvements in hemoglobin levels and iron parameters, with good tolerability in that patient population. When used as a phosphate binder in patients with dialysis-dependent CKD, ferric citrate also improved hemoglobin and iron parameters; additional trials are needed to assess efficacy.
There are other novel iron preparations in development, including ferric maltol (approved in Europe and the United States for IDA in adults) and Sucrosomial® iron that has been evaluated in IDA associated with CKD and several other clinical settings.
Read More at: ACKD Journal